Annual report

News

PRAC June 2024 – PRAC started review of painkiller metamizole and identified risk of secondary malignancies of T-cell origin with CAR T-cell medicines

During its June 2024 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency started a review of the painkiller metamizole and identified a risk of secondary malignancies of T-cell origin with CAR T- cell medicines.

Total sales of antibiotics for animals in Belgium continued to fall in 2023

Total sales of antibiotics for animals in Belgium fell sharply in 2023: 21.7% compared to 2022, with a cumulative reduction of 62.4% compared to 2011 (reference year). Overall, the results of antibiotic resistance monitoring in food-producing animals are favourable. New initiatives are needed to support all stakeholders in their efforts to use antibiotics in a reduced, careful and rational way, to ensure the sustainable use of antibiotics in the future.

Overview of FAMHP achievements and accomplishments in the context of the Belgian presidency

From 1 January 2024 to 30 June 2024, Belgium chaired the Council of the European Union, the body in which the 27 member states set the political direction and priorities of the European Union. During this period, the FAMHP organised over 20 events and meetings to promote cooperation and dialogue among member states and with European institutions. In addition, the FAMHP provided expertise to many important European initiatives. Time for a recap.

The FAMHP publishes its 2023 annual report: all our figures, results and main projects

Although 2023 saw an increase in notifications regarding temporary unavailability of medicines, the agency once again demonstrated its effectiveness in ensuring the most efficient possible management of medicine stocks, as in the case of thrombolytics. The FAMHP also played its part in protecting public health by increasing the number of investigations into illegal medicines and devices by 30 %, and of inspections of pharmacies open to the public by over 40 %.